This assay was instrumental in identifying an augmented activation potential of EBV-specific IgG in patients with a complete hereditary deficiency of FcγRIIIA/CD16A suffering from persistent EBV infection (33). This evidence concerns the gene FCGR3A and Epstein-Barr virus infection.